TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35986258

Group type: EXPERIMENTAL
Intervention: Nulligravida
Number of subjects: 22545

Group type: EXPERIMENTAL
Intervention: Gravida/nulliparous
Number of subjects: 22545

Group type: EXPERIMENTAL
Intervention: Interpregnancy intervals less than 18 months
Number of subjects: 22545

Group type: EXPERIMENTAL
Intervention: Poor appetite/vomiting in the second trimester
Number of subjects: 22545

Group type: EXPERIMENTAL
Intervention: Greater wealth
Number of subjects: 22545

Group type: EXPERIMENTAL
Intervention: Swelling of hands/face in the third trimester
Number of subjects: 22545

Group type: EXPERIMENTAL
Intervention: Parity greater than five
Number of subjects: 22545

Group type: EXPERIMENTAL
Intervention: Male fetal sex
Number of subjects: 22545

Group type: EXPERIMENTAL
Intervention: Increased weight gain
Number of subjects: 22545
Study: 35986306

Group type: EXPERIMENTAL
Intervention: Parenting interventions focusing on promoting parental reflective function (RF)
Number of subjects: 0
Study: 35986671

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir plus rilpivirine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Daily dolutegravir-abacavir-lamivudine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 12
Study: 35986750

Group type: EXPERIMENTAL
Intervention: VA-ECMO treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard advanced cardiac life support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VA-ECMO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venting strategies
Number of subjects: 0
Study: 35986823

Group type: EXPERIMENTAL
Intervention: EGFR positivity (negative, mild, moderate, severe)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mean C-reactive protein (CRP) values
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mean D-dimer values
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mean length of stay in the ICU
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methylprednisolone dose
Number of subjects: 50

Group type: COMPARATOR
Intervention: Presence of comorbidity
Number of subjects: 50
Study: 35986824

Group type: EXPERIMENTAL
Intervention: p-ARDS
Number of subjects: 39

Group type: COMPARATOR
Intervention: ep-ARDS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PFT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Correlation
Number of subjects: 39
Study: 35986865

Group type: EXPERIMENTAL
Intervention: Hemopatch
Number of subjects: 0
Study: 35987165

Group type: EXPERIMENTAL
Intervention: Isatuximab plus atezolizumab (Isa + Atezo)
Number of subjects: 107
Study: 35987601

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) treatment
Number of subjects: 1317
Study: 35987625

Group type: EXPERIMENTAL
Intervention: Outpatient visits for pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatient admissions for malaria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient visits for malaria in Mozambique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatient admissions for malaria in Mozambique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall treatment costs for malaria and pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timely treatment for malaria and pneumonia
Number of subjects: 0
Study: 35987700

Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 2475

Group type: EXPERIMENTAL
Intervention: Intense physical activity
Number of subjects: 2475

Group type: EXPERIMENTAL
Intervention: Total physical activity classified as NVA
Number of subjects: 2475

Group type: EXPERIMENTAL
Intervention: Intense physical activity classified as NVA
Number of subjects: 2475

Group type: EXPERIMENTAL
Intervention: Total physical activity classified as EVA
Number of subjects: 2475

Group type: EXPERIMENTAL
Intervention: Intense physical activity classified as EVA
Number of subjects: 2475

Group type: COMPARATOR
Intervention: Moderate- or low-intensity physical activity
Number of subjects: 2475
Study: 35987704

Group type: EXPERIMENTAL
Intervention: Smoking cessation pharmacotherapy (7.2% of current smokers)
Number of subjects: 40004

Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 40004

Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 40004

Group type: COMPARATOR
Intervention: Patients who stopped smoking 0-1 day before surgery
Number of subjects: 40004

Group type: COMPARATOR
Intervention: Patients who stopped smoking 2-14 days before surgery
Number of subjects: 40004

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 40004

Group type: EXPERIMENTAL
Intervention: Having recent coronary artery disease
Number of subjects: 40004

Group type: EXPERIMENTAL
Intervention: Having cancer
Number of subjects: 40004

Group type: EXPERIMENTAL
Intervention: Undergoing major vascular surgery
Number of subjects: 40004

Group type: EXPERIMENTAL
Intervention: Undergoing urgent/emergent surgery
Number of subjects: 40004

Group type: EXPERIMENTAL
Intervention: Undergoing thoracic surgery
Number of subjects: 40004
Study: 35987706

Group type: EXPERIMENTAL
Intervention: Artificial-intelligence colour overlay
Number of subjects: 40
Study: 35987977

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 890

Group type: COMPARATOR
Intervention: Intravenous lorazepam
Number of subjects: 890
Study: 35987988

Group type: EXPERIMENTAL
Intervention: Artichoke freeze-dried extract (AWPC)
Number of subjects: 18
Study: 35988541

Group type: EXPERIMENTAL
Intervention: Vaccinated humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccinated BALB/c mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-human primates
Number of subjects: 0
Study: 35988545

Group type: EXPERIMENTAL
Intervention: Triple therapy with obinutuzumab, acalabrutinib, and venetoclax after optional debulking with bendamustine
Number of subjects: 45
Study: 35988546

Group type: EXPERIMENTAL
Intervention: Mitapivat (5 mg, 20 mg, 50 mg twice daily during a 16-week dose-optimisation period followed by a 24-week fixed-dose period)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 27
Study: 35988689

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) in individuals with NAFL
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) in individuals with NASH
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) across all groups
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) from individuals with NASH
Number of subjects: 66
Study: 35988815

Group type: EXPERIMENTAL
Intervention: LDN + tDCS
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: LDN + tDCS Sham
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo + tDCS
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo + tDCS Sham
Number of subjects: 86
Study: 35989352

Group type: EXPERIMENTAL
Intervention: Diaphragmatic thickening fraction (DTF) measured within 24 hours since the start of weaning, median DTF 28% (IQR 22-39%)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: RASS score
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Kelly-Matthay score
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Inspiratory oxygen fraction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial failure
Number of subjects: 57
Study: 35989614

Group type: EXPERIMENTAL
Intervention: Mothers carrying a male foetus
Number of subjects: 139

Group type: COMPARATOR
Intervention: Mothers carrying a female foetus
Number of subjects: 139
Study: 35989865

Group type: EXPERIMENTAL
Intervention: Assessment and treatment by primary care physicians
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Identification of medication nonadherence
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Identification of drug-drug interactions (DDIs)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Identification of disease progression
Number of subjects: 246
Study: 35989924

Group type: EXPERIMENTAL
Intervention: Bridging intravenous thrombolysis (IVT)
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Prior medication with Vitamin K antagonists (VKA)
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Higher admission National Institutes of Health Stroke Scale (NIHSS) score
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 1347
Study: 35990111

Group type: EXPERIMENTAL
Intervention: Tele-yoga intervention (two one-on-one 30-minute sessions weekly for a total of 12 sessions)
Number of subjects: 16
Study: 35990326

Group type: EXPERIMENTAL
Intervention: High Protein Diet (HP)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Recommended Protein Diet (RP)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control Diet (CON)
Number of subjects: 136
Study: 35990750

Group type: EXPERIMENTAL
Intervention: Accelerated evaluation
Number of subjects: 175

Group type: COMPARATOR
Intervention: Historical cohort (standard of care)
Number of subjects: 175
Study: 35990945

Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m²) in non-ischemic HFpEF
Number of subjects: 3360

Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m²) in ischemic HFpEF
Number of subjects: 3360

Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m²) in both non-ischemic and ischemic HFpEF during short-term follow-up
Number of subjects: 3360

Group type: EXPERIMENTAL
Intervention: Class III obesity in ischemic HFpEF
Number of subjects: 3360
Study: 35990971

Group type: EXPERIMENTAL
Intervention: Patients with no SMuRFs (SMuRFless)
Number of subjects: 2046

Group type: COMPARATOR
Intervention: Patients with at least one SMuRF
Number of subjects: 2046
Study: 35990987

Group type: EXPERIMENTAL
Intervention: LA acceleration factor derived from magnetic resonance (MR) four-dimensional (4D) flow imaging
Number of subjects: 62
Study: 35991364

Group type: EXPERIMENTAL
Intervention: Dental emergency unit (DEU) intervention during COVID-19
Number of subjects: 299
Study: 35992565

Group type: EXPERIMENTAL
Intervention: edoxaban
Number of subjects: 316

Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 316
Study: 35992822

Group type: EXPERIMENTAL
Intervention: JMT103 at 0.5, 1.0, 2.0, and 3.0 mg/kg every 4 weeks for 3 cycles
Number of subjects: 59
Study: 35992850

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnostic model
Number of subjects: 719
Study: 35992943

Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation contacts
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ring contacts
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Active stimulation sites
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Contacts in closest proximity to internal capsule
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DBS leads
Number of subjects: 31
Study: 35993306

Group type: EXPERIMENTAL
Intervention: Postneoadjuvant treatments (e.g., capecitabine, Olaparib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 3 approaches (e.g., circulating tumour DNA)
Number of subjects: 0
Study: 35993829

Group type: EXPERIMENTAL
Intervention: Neutral/cushioned running shoes
Number of subjects: 11240

Group type: COMPARATOR
Intervention: Motion control shoes
Number of subjects: 11240

Group type: COMPARATOR
Intervention: Soft midsole shoes
Number of subjects: 11240

Group type: COMPARATOR
Intervention: Stability shoes
Number of subjects: 11240

Group type: COMPARATOR
Intervention: Running shoes prescribed based on foot posture
Number of subjects: 11240
Study: 35994321

Group type: EXPERIMENTAL
Intervention: Active Video Game-based intervention (12 weekly sessions) with game-based pedometers, PA behavioral coaching, and survivorship navigation discussions.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (existing breast cancer support group) with conventional pedometers.
Number of subjects: 60
Study: 35994340

Group type: EXPERIMENTAL
Intervention: Therapeutic video game (TVG) used for 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Therapeutic video game (TVG)
Number of subjects: 15
Study: 35994729

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) metrics
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CGM metrics from remitters
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Thorough CGM analysis
Number of subjects: 78

Group type: COMPARATOR
Intervention: Residual β-cell secretion estimates
Number of subjects: 78
Study: 35994746

Group type: EXPERIMENTAL
Intervention: Maternal RBC folate concentrations
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Maternal RBC folate concentrations ≥906 nmol/L
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Mendelian randomization of maternal RBC folate concentrations
Number of subjects: 985
Study: 35995129

Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring starting within 6 hours of birth for 72 hours, followed by interventions based on clinical condition.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interventions following a standard treatment algorithm for persistent cerebral desaturation.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring.
Number of subjects: 100
Study: 35995551

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) thalamotomy
Number of subjects: 100
Study: 35995696

Group type: EXPERIMENTAL
Intervention: Autologous CIK cells therapy combined with Sintilimab and platinum-based doublet chemotherapy
Number of subjects: 34
Study: 35995702

Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Number of subjects: 15
Study: 35995934

Group type: EXPERIMENTAL
Intervention: Reinfection after initial COVID-19 infection
Number of subjects: 1806

Group type: COMPARATOR
Intervention: Second COVID-19 infections
Number of subjects: 1806

Group type: COMPARATOR
Intervention: Reinfection mortality
Number of subjects: 1806

Group type: COMPARATOR
Intervention: Vaccination status before second infection
Number of subjects: 1806
Study: 35996071

Group type: EXPERIMENTAL
Intervention: Logistic regression model incorporating intraoperative vital signs and preoperative predictors.
Number of subjects: 30619

Group type: EXPERIMENTAL
Intervention: Preoperative factors
Number of subjects: 30619

Group type: EXPERIMENTAL
Intervention: Intraoperative predictors
Number of subjects: 30619
Study: 35996089

Group type: EXPERIMENTAL
Intervention: Smart-clothes assisted home nursing program (smart-vest)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard care (without smart-vest)
Number of subjects: 12
Study: 35996147

Group type: EXPERIMENTAL
Intervention: Kidney Disease Index (KDI)
Number of subjects: 9115

Group type: EXPERIMENTAL
Intervention: 1/eGFR and ln [ACR×100]
Number of subjects: 9115
Study: 35996565

Group type: EXPERIMENTAL
Intervention: AZD1656 (100mg twice a day)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: AZD1656
Number of subjects: 156
Study: 35996930

Group type: EXPERIMENTAL
Intervention: Psoriatic Arthritis (PsA) patients with axial involvement
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Psoriatic Arthritis (PsA) patients without axial involvement
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Methotrexate and sulfasalazine (disease-modifying antirheumatic drugs)
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Psoriatic Spondylitis patients
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Korean patients with PsA requiring biologics
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Psoriatic Spondylitis
Number of subjects: 2330
Study: 35997582

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 0
Study: 35997608

Group type: EXPERIMENTAL
Intervention: Photoacoustic imaging to measure synovial oxygenation status
Number of subjects: 0
Study: 35997700

Group type: EXPERIMENTAL
Intervention: Exalt
Number of subjects: 201

Group type: COMPARATOR
Intervention: aScope Duodeno
Number of subjects: 201
Study: 35998100

Group type: EXPERIMENTAL
Intervention: GoNoodle Plus (GN)
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Take10
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: ABC for Fitness (ABC)
Number of subjects: 1098
Study: 35998103

Group type: EXPERIMENTAL
Intervention: Lack of access to running water
Number of subjects: 1634

Group type: COMPARATOR
Intervention: Cigarette smoke exposure
Number of subjects: 1634

Group type: COMPARATOR
Intervention: Wood-burning stove use
Number of subjects: 1634

Group type: COMPARATOR
Intervention: Number of persons living in the household
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: Hearing loss in children aged 3 to 6 years
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: Hearing loss in children aged 7 years and older
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: Middle ear disease in children aged 3 to 6 years
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: Middle ear disease in children aged 7 years and older
Number of subjects: 1634
Study: 35998206

Group type: EXPERIMENTAL
Intervention: 4-day controlled vegetarian diet intervention
Number of subjects: 36
Study: 35998303

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 0
Study: 35998695

Group type: COMPARATOR
Intervention: Active asthma diagnosis in dairy farmers
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Family history of allergy
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Personal history of eczema
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Hay manipulation
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Farm area
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Handling treated seeds
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Family history of allergy (compared to control non-farm employees)
Number of subjects: 1203
Study: 35998959

Group type: EXPERIMENTAL
Intervention: Incident COVID-19
Number of subjects: 16910

Group type: EXPERIMENTAL
Intervention: Long COVID (defined as symptoms lasting more than 4 weeks after disease onset)
Number of subjects: 16910
Study: 35998971

Group type: EXPERIMENTAL
Intervention: Perioperative mental health intervention bundle (behavioural activation and medication optimisation)
Number of subjects: 0
Study: 35999035

Group type: EXPERIMENTAL
Intervention: RRS cluster
Number of subjects: 8266

Group type: EXPERIMENTAL
Intervention: ULE cluster
Number of subjects: 8266

Group type: EXPERIMENTAL
Intervention: AD cluster
Number of subjects: 8266

Group type: EXPERIMENTAL
Intervention: SE cluster
Number of subjects: 8266

Group type: COMPARATOR
Intervention: Cox-proportional hazard test
Number of subjects: 8266
Study: 35999221

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (radiation-attenuated Plasmodium falciparum sporozoites)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35999229

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 53
Study: 35999380

Group type: EXPERIMENTAL
Intervention: Definite mNE
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Possible mNE
Number of subjects: 575

Group type: COMPARATOR
Intervention: Unexposed
Number of subjects: 575
Study: 35999387

Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 0
Study: 35999466

Group type: EXPERIMENTAL
Intervention: Pre-operative psychological state (measured by Pain Catastrophizing Score, PCS)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Joint pain at rest (measured using Visual Analogue Scale 0-100)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (measured using Beck Depression Inventory or Geriatric Depression Score)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Situational anxiety and dispositional anxiety (measured using State-Trait Inventory)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Joint function (assessed using Western Ontario and McMaster Universities Osteoarthritis Index for hip and knee and Oxford Shoulder Score for shoulder)
Number of subjects: 266
Study: 35999520

Group type: EXPERIMENTAL
Intervention: Serum phosphate concentration
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pre-hemodialysis blood pressure measurements
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Total peripheral resistance index (TPRI)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Plasma levels of endothelin-1 (ET-1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA)
Number of subjects: 54
Study: 35999522

Group type: EXPERIMENTAL
Intervention: Transient Fear of Falling (T-FoF)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Persistent Fear of Falling (P-FoF)
Number of subjects: 389

Group type: COMPARATOR
Intervention: No Fear of Falling (No-FoF)
Number of subjects: 389

Group type: COMPARATOR
Intervention: T-FoF vs No-FoF
Number of subjects: 389

Group type: COMPARATOR
Intervention: P-FoF vs No-FoF
Number of subjects: 389

Group type: COMPARATOR
Intervention: T-FoF vs P-FoF
Number of subjects: 389
Study: 35999546

Group type: EXPERIMENTAL
Intervention: Cumulative TyG index (very high group)
Number of subjects: 5695

Group type: EXPERIMENTAL
Intervention: Cumulative TyG index
Number of subjects: 5695
Study: 35999585

Group type: EXPERIMENTAL
Intervention: Feedback on patient-reported outcome measures (PROMs) in a web-based personalized decision report
Number of subjects: 25
Study: 35999616

Group type: EXPERIMENTAL
Intervention: POSITIVE system (home-monitoring equipment and communication platform)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: POSITIVE system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (medical review, nutritional recommendations, and Vivifrail physical exercise program)
Number of subjects: 50
Study: 35999633

Group type: EXPERIMENTAL
Intervention: Pre-admission telephone reminder
Number of subjects: 262

Group type: COMPARATOR
Intervention: No pre-admission telephone reminder (non-intervention)
Number of subjects: 262
Study: 36000222

Group type: EXPERIMENTAL
Intervention: Oral iron (ferrous sulphate, 120 mg elemental iron)
Number of subjects: 15
Study: 36000427

Group type: EXPERIMENTAL
Intervention: Paroxetine-mediated G-protein receptor kinase 2 inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36000434

Group type: EXPERIMENTAL
Intervention: LDL-C ≥100 mg/dL
Number of subjects: 5532

Group type: EXPERIMENTAL
Intervention: LDL-C 70-99 mg/dL
Number of subjects: 5532

Group type: EXPERIMENTAL
Intervention: LDL-C <70 mg/dL
Number of subjects: 5532

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 5532